In the future, well-designed cohort studies with a larger sample size and more complete follow-up data, as well as in-depth molecular mechanism researches are needed to elucidate the role of CD44 and ZEB1 in the chemoresistance of ovarian cancer. This evidence concerns the gene CD44 and ovarian carcinoma.